Furthermore, a phase I clinical trial of neoadjuvant intraprostatic injection of GLIPR1 delivered by adenoviral vector for localized and intermediate and high-risk prostate cancer before radical prostatectomy showed antitumor activity and favorable modulation of blood-based biomarkers of immune stimulation [14]. This evidence concerns the gene GLIPR1 and Familial prostate cancer.